Revelation Biosciences获得了其Gemini疗法的FDA认可，并报告了积极的试验结果，推动了其在肾损伤和感染领域的研发。 Revelation Biosciences secured FDA acceptance for its Gemini therapy and reported positive trial results, advancing its development for kidney injury and infections.

启示生物科学公司确认已达到2025年12月3日特别会议的议员定数,并敦促股东在12月2日前投票. Revelation Biosciences confirmed it has achieved a quorum for its December 3, 2025, special meeting and urged shareholders to vote by December 2. 公司报告称，FDA已接受其Gemini疗法第一阶段结束会议方案，旨在推动急性肾损伤的开发。 The company reported FDA acceptance of its end-of-phase 1 meeting package for its Gemini therapy, aiming to advance development for acute kidney injury. 它还分享了PRIME研究的积极的收入结果,并通过令状诱导筹集了960万美元. It also shared positive top-line results from its PRIME study and raised $9.6 million through a warrant inducement. 正在对Gemini进行急性和慢性肾病及外科后感染的评估。 Gemini is being evaluated for acute and chronic kidney disease and post-surgical infections. 前瞻性声明告诫说,实际结果可能因临床、监管、金融和竞争风险而异。 Forward-looking statements caution that actual results may vary due to clinical, regulatory, financial, and competitive risks.